Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED
Status:
Completed
Trial end date:
2017-08-24
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of a single intracavernous injection of hMaxi K (8000 µg
and 16000 µg) or placebo upon penile rigidity or erection in males with erectile dysfunction
longer than six months that is attributable to an underlying, stable medical condition.